Tempus

Tempus offers AI-powered precision medicine solutions that give healthcare providers the insights and information they need to make more effective cancer treatments. By combining a large library of clinical and molecular data, Tempus accelerates the discovery of new targets, predicts treatment response, identifies life-saving clinical trials, and improves diagnosis.

Some of the key features include:

• ONE: An AI-powered clinical assistant that gives clinicians patient insights right in the moment of care.
• NEXT: Identifies gaps in care and helps to close them for better patient outcomes.
• LENS: Provides access to and analysis of multimodal real-world data.
• ALGOS: Algorithmic models integrated with assays for deeper insights.

Tempus serves a range of customers:

• Providers: Helps physicians make more informed treatment decisions.
• Life Sciences: Helps pharmaceutical and biotech companies develop better drugs.
• Patients: Helps patients get personalized treatment options.

Scientific publications have validated the power of Tempus' platform:

• A study in Nature Biotechnology shows that Tempus' xT Platform opens up more personalized therapeutic options for cancer patients.
• A Pan-cancer Organoid Platform for Precision Medicine study shows the power of a neural-network-based approach for predicting patient-specific drug responses.
• Validation of a liquid biopsy assay shows the power of combining liquid biopsies with standard tissue genotyping.

Tempus has partnerships with more than 65% of all Academic Medical Centers in the US and has partnered with more than 95% of top 20 pharma oncology companies. The company has also received FDA Breakthrough Device Designation for its HLA-LOH Companion Diagnostic Test and launched an RNA sequencing test, Tempus xR.

Tempus is dedicated to improving patient care through high-quality testing, clinical trial matching, and deep research data, and to transforming personalized patient care.

Published on June 14, 2024